Alban Ziegler,Carrie Koval-Burt,Denise M Kay,Sharon F Suchy,Amber Begtrup,Katherine G Langley,Rebecca Hernan,Laura M Amendola,Brenna M Boyd,Jennifer Bradley,Tracy Brandt,Lilian L Cohen,Alison J Coffey,Joseph M Devaney,Beata Dygulska,Bethany Friedman,Ramsay L Fuleihan,Awura Gyimah,Sihoun Hahn,Sean Hofherr,Kathleen S Hruska,Zhanzhi Hu,Médéric Jeanne,Guanjun Jin,D Aaron Johnson,Haluk Kavus,Rudolph L Leibel,Steven J Lobritto,Stephen McGee,Joshua D Milner,Kirsty McWalter,Kristin G Monaghan,Jordan S Orange,Nicole Pimentel Soler,Yeyson Quevedo,Samantha Ratner,Kyle Retterer,Ankur Shah,Natasha Shapiro,Robert J Sicko,Eric S Silver,Samuel Strom,Rebecca I Torene,Olatundun Williams,Vincent D Ustach,Julia Wynn,Ryan J Taft,Paul Kruszka,Michele Caggana,Wendy K Chung

Abstract:Importance: The feasibility of implementing genome sequencing as an adjunct to traditional newborn screening (NBS) in newborns of different racial and ethnic groups is not well understood. Objective: To report interim results of acceptability, feasibility, and outcomes of an ongoing genomic NBS study in a diverse population in New York City within the context of the New York State Department of Health Newborn Screening Program. Design, setting, and participants: The Genomic Uniform-screening Against Rare Disease in All Newborns (GUARDIAN) study was a multisite, single-group, prospective, observational investigation of supplemental newborn genome screening with a planned enrollment of 100 000 participants. Parent-reported race and ethnicity were recorded at the time of recruitment. Results of the first 4000 newborns enrolled in 6 New York City hospitals between September 2022 and July 2023 are reported here as part of a prespecified interim analysis. Exposure: Sequencing of 156 early-onset genetic conditions with established interventions selected by the investigators were screened in all participants and 99 neurodevelopmental disorders associated with seizures were optional. Main outcomes and measures: The primary outcome was screen-positive rate. Additional outcomes included enrollment rate and successful completion of sequencing. Results: Over 11 months, 5555 families were approached and 4000 (72.0%) consented to participate. Enrolled participants reflected a diverse group by parent-reported race (American Indian or Alaska Native, 0.5%; Asian, 16.5%; Black, 25.1%; Native Hawaiian or Other Pacific Islander, 0.1%; White, 44.7%; 2 or more races, 13.0%) and ethnicity (Hispanic, 44.0%; not Hispanic, 56.0%). The majority of families consented to screening of both groups of conditions (both groups, 90.6%; disorders with established interventions only, 9.4%). Testing was successfully completed for 99.6% of cases. The screen-positive rate was 3.7%, including treatable conditions that are not currently included in NBS. Conclusions and relevance: These interim findings demonstrate the feasibility of targeted interpretation of a predefined set of genes from genome sequencing in a population of different racial and ethnic groups. DNA sequencing offers an additional method to improve screening for conditions already included in NBS and to add those that cannot be readily screened because there is no biomarker currently detectable in dried blood spots. Additional studies are required to understand if these findings are generalizable to populations of different racial and ethnic groups and whether introduction of sequencing leads to changes in management and improved health outcomes. Trial registration: ClinicalTrials.gov Identifier: NCT05990179.

Lessons Learned from Expanded Reproductive Carrier Screening in Self‐reported Ashkenazi, Sephardi, and Mizrahi Jewish Patients

Carrier Burden of over 300 Diseases in Han Chinese Identified by Expanded Carrier Testing of 300 Couples Using Assisted Reproductive Technology.

Expanded targeted preconception screening panel in Israel: findings and insights

Creation of a National, At-home Model for Ashkenazi Jewish Carrier Screening

A Capillary Electrophoresis-Based Multiplex PCR Assay for Expanded Carrier Screening in the Eastern Han Chinese Population

Expanded carrier screening for inherited genetic disease using exome and genome sequencing

An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy

Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years

Customizing carrier screening in the Chinese population: Insights from a 334‐gene panel

Clinical Utility of Expanded Carrier Screening in the Preconception and Prenatal Population: A Chinese Cohort Study

Expanding families: a pilot study on preconception expanded carrier screening in Bahrain

Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions

Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population

Pilot study of expanded carrier screening for 11 recessive diseases in China: results from 10,476 ethnically diverse couples

Asian Screening Array and Next-Generation Sequencing Based Panels Applied to Preimplantation Genetic Testing for Monogenic Disorders Preclinical Workup in 294 Families: A Retrospective Analysis

[Expanded carrier screening for 216 diseases in a cohort of 3 097 healthy Chinese individuals of childbearing age].

Implementation of a Carrier Screening Program in a High-Risk Undergraduate Student Population Using Digital Marketing, Online Education, and Telehealth

Understanding Social, Cultural, and Religious Factors Influencing Medical Decision-Making on BRCA1/2 Genetic Testing in the Orthodox Jewish Community

Estimating at-risk couple rates across 1000 exome sequencing data cohort for 176 genes and its importance relevance for health policies

BRCA awareness and testing experience in the UK Jewish population: a qualitative study

Clinical Utility of Medical Exome Sequencing: Expanded Carrier Screening for Patients Seeking Assisted Reproductive Technology in China